Pharma Pulse: RSV Protection Wanes, AstraZeneca Invests Big, and Novo Nordisk Faces Pipeline Setback

Nov 25, 12:55 PM

Headliner
Share
Subscribe
A new Pharma Pulse unpacks declining RSV vaccine durability in older adults, AstraZeneca’s $2 billion expansion of its US biologics manufacturing footprint, and the stock-shaking Phase III struggle affecting Novo Nordisk’s Alzheimer’s ambitions.
Share
Subscribe
Next
Pharma Pulse: Medicare Price Negotiations Heat Up, as FDA Approves SMA Gene Therapy
Top episodes
Incorporating AI into Commercialization Plans
by Pharmaceutical Commerce
Overcoming Supply Chain Challenges
by Pharmaceutical Commerce
The Capabilities of a 3PL Provider
by Pharmaceutical Commerce